TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME
摘要:
Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.
NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
申请人:Merck Sharp & Dohme Corp.
公开号:US20190144433A1
公开(公告)日:2019-05-16
Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof:
Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
A fluorine scan of non-peptidic inhibitors of neprilysin: Fluorophobic and fluorophilic regions in an enzyme active site
作者:Martin Morgenthaler、Johannes D. Aebi、Fiona Grüninger、Daniel Mona、Björn Wagner、Manfred Kansy、François Diederich
DOI:10.1016/j.jfluchem.2008.02.004
日期:2008.9
close contacts of organicfluorine with the negatively polarized π-surfaces of surrounding aromatic amino acid side chains. In contrast, the protein environment around the benzimidazole platform, with three electropositive guanidinium side chains of Arg residues, was found to provide a fluorophilic environment. Overall, the data support that organicfluorine, with its high negative charge density prefers
本文介绍了合成方法和体外(聚)氟化中性溶酶抑制剂的生物亲和力。研究了两个系列的配体中心苯并咪唑平台的F取代抑制剂和填充NEP S1'口袋的苄基载体。S1'口袋被发现具有高度的疏水性,F取代导致抑制剂的结合亲和力大大降低。该结果由有机氟在静电上不利地与周围的芳香族氨基酸侧链的负极化π表面紧密接触来解释。相反,发现苯并咪唑平台周围的蛋白质环境具有Arg残基的三个正电胍基侧链,提供了亲氟环境。总体而言,数据支持有机氟,具有高负电荷密度的电子更倾向于定向到受体位点的正电区域。p氟化配体的K a测量为预测苯并咪唑的p K a值提供了几种简单的模式,苯并咪唑是药物化学中的重要组成部分。
Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.